BioGeneration Ventures — 2020 Investments
3 investments dated 2020 · listed companies and verified rows first · show all
Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones.
BiotechHealthtechMedical DevicesOss, NL
Renato Chirivi(Co-founder (former CSO))in
BoardPaul Peter Tak(Chair of the Board)
Co-investorsPureos BioventuresForbionJohnson & Johnson Innovation – JJDCSeventure PartnersBOMCurie Capital+1 more
AiDASH uses satellite imagery and AI to help industries become more resilient, efficient, and sustainable.
AI & Machine LearningCleantechClimate TechEnergySaaSSanta Clara, US
Abhishek Vinod Singh(Chief Executive Officer)in
Co-investorsG2 Venture PartnersNational Grid PartnersSE VenturesThe Lightsmith GroupUnanimous CapitalBenhamou Global Ventures+1 more
CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.
BiotechDeep TechHealthtechMunich, DE
Jörg Wischhusen(Scientific Co-founder)Scott Clarke(Chief Executive Officer)inPeter Garcia(Chief Financial Officer)Sujata Rao(Chief Medical Officer)inStefan Ries(Chief Scientific Officer and Head of Munich Site)inAndrea Goddard(Chief Technical Officer)in
Co-investorsJeito CapitalBioqube VenturesForbionBayern KapitalCanaan PartnersNovartis Venture Fund+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.